Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM50 is a member of the tripartite motif (TRIM) protein family, characterized by a RING domain, B-box motif, and coiled-coil region[2]. TRIM50 acts as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin to substrate proteins by interacting preferentially with E2 conjugating enzymes such as UbcH8, UbcH6, and UbcH9 through its RING domain[2]. In cellular contexts, TRIM50 shows high specificity for gastric parietal cells; it is predominantly localized in tubulovesicular and canalicular membranes within these cells, contributing to vesicular trafficking and dynamics essential for gastric acid secretion[1]. TRIM50-associated vesicular movement is phosphoinositide 3-kinase (PI3K)-dependent and involves binding of its C-terminal PRY-SPRY domain to phosphatidylinositol phosphates. Knockout studies in mice show that loss of TRIM50 leads to impaired gastric acid secretion and abnormal vesicular morphology without affecting overall cell viability or the normal expression of acid-secretory machinery[1]. TRIM50 forms higher-order structures, possibly trimers, and localizes to cytoplasmic aggregates (aggresomes) that may be involved in protein quality control and degradation[2]. TRIM50's gene is located in a region deleted in Williams–Beuren syndrome, suggesting possible relevance to this disorder[2]. At present, TRIM50 has no known direct drug modulators or established therapeutic interventions, and its role as a biomarker or therapeutic target remains under investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM50 (TRIM50).